









Markets
/
Stocks
/
nasdaq-mbrx
/

Moleculin Biotech Inc

MBRX

4.310USD

+0.400+10.23%

Close 02/06, 16:00（ET）Quotes delayed by 15 min

8.53MMarket Cap

LossP/E TTM



Moleculin Biotech Inc

4.310

+0.400+10.23%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Moleculin Biotech Inc

Currency: USD Updated: 2026-02-06

Key Insights

Moleculin Biotech Inc's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 158 out of 392 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 24.33.In the medium term, the stock price is expected to trend down.The company has been performing well in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Moleculin Biotech Inc's Score

Industry at a Glance

Industry Ranking

158 / 392

Overall Ranking

305 / 4521

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Neutral

Moleculin Biotech Inc Highlights

StrengthsRisks

Moleculin Biotech, Inc. is a Phase III clinical-stage pharmaceutical company advancing a pipeline of therapeutic candidates addressing tumors and viruses. The Company is conducting a pivotal Phase III trial evaluating Annamycin, a non-cardiotoxic anthracycline, in combination with Cytarabine for the treatment of subjects with relapsed/refractory acute myeloid leukemia (AML). It has three core technologies and six drug candidates, three of which have shown human activity in clinical trials. Its core technologies consist of Annamycin, WP1066 Portfolio, and WP1122 Portfolio. Annamycin is designed to avoid multidrug resistance mechanisms and cardiotoxicity. Its WP1066, is an Immune/Transcription Modulator capable of inhibiting p-STAT3 and other transcription factors, and its portfolio includes WP1193, and WP1220. Its WP1122 contains compounds including WP1096, and WP1097, which is designed to exploit the potential uses of inhibitors of glycolysis such as 2-deoxy-D-glucose (2-DG).

Fairly Valued

The company’s latest PE is -0.09, at a medium 3-year percentile range.

Institutional Selling

The latest institutional holdings are 40.50K shares, decreasing 49.44% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 15.54K shares of this stock.

Lower Market Activity

The company has less investor interest, with a 20-day turnover ratio of -0.47.

Analyst Rating

Based on 3 analysts

Buy

Current Rating

24.333

Target Price

+522.34%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-02-06

The current financial score of Moleculin Biotech Inc is 6.97, ranking 176 out of 392 in the Biotechnology & Medical Research industry. Its financial status is robust, and its operating efficiency is low.

Score

Industry at a Glance

Previous score

6.97

Change



Financials

10.00

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

7.05

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

4.00

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

6.75

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.03

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

Moleculin Biotech Inc's Company Valuation

Currency: USD Updated: 2026-02-06

The current valuation score of Moleculin Biotech Inc is 6.13, ranking 328 out of 392 in the Biotechnology & Medical Research industry. Its current P/E ratio is -0.09, which is -92.06% below the recent high of -0.01 and -3747.32% above the recent low of -3.59.

Score

Industry at a Glance

Previous score

6.13

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 158/392

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-02-06

The current earnings forecast score of Moleculin Biotech Inc is 8.00, ranking 164 out of 392 in the Biotechnology & Medical Research industry. The average price target is 100.00, with a high of 300.00 and a low of 100.00.

Score

Industry at a Glance

Previous score

8.00

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 3 analysts

Buy

Current Rating

24.333

Target Price

+522.34%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

542

Total

Median

Average

Company name

Ratings

Analysts

Moleculin Biotech Inc

MBRX

CRISPR Therapeutics AG

CRSP

IQVIA Holdings Inc

IQV

argenx SE

ARGX

Beigene Ltd

ONC

Intellia Therapeutics Inc

NTLA

...

109

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-02-06

The current price momentum score of Moleculin Biotech Inc is 6.56, ranking 224 out of 392 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 5.02 and the support level at 3.72, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.03

Change

0.53

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(2)

Neutral(3)

Buy(2)

Indicators

Value

Direction

MACD(12,26,9)

0.109

Neutral

RSI(14)

46.134

Neutral

STOCH(KDJ)(9,3,3)

33.128

Buy

ATR(14)

0.383

High Vlolatility

CCI(14)

-60.895

Neutral

Williams %R

64.607

Sell

TRIX(12,20)

-0.210

Sell

StochRSI(14)

100.000

Buy

Moving Average

Sell(4)

Neutral(0)

Buy(2)

Indicators

Value

Direction

MA5

4.142

Buy

MA10

4.294

Buy

MA20

4.315

Sell

MA50

4.808

Sell

MA100

8.223

Sell

MA200

12.576

Sell

Institutional Confidence

Currency: USD Updated: 2026-02-06

The current institutional shareholding score of Moleculin Biotech Inc is 3.00, ranking 197 out of 392 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 1.50%, representing a quarter-over-quarter increase of 11.40%. The largest institutional shareholder is The Vanguard, holding a total of 15.54K shares, representing 0.58% of shares outstanding, with 161.13% increase in holdings.

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

Klemp (Walter V.)

30.61K

+0.00%

The Vanguard Group, Inc.

Star Investors

9.60K

+675.83%

Foster (Jonathan P.)

12.13K

+0.01%

Geode Capital Management, L.L.C.

8.33K

+656.40%

UBS Financial Services, Inc.

159.00

-50.31%

HRT Financial LP

4.61K

LPL Financial LLC

2.32K

+3.57%

IEQ Capital LLC

1.46K

Wealth Dimensions Group, Ltd.

800.00

Picker (Donald H)

671.00

Risk Assessment

Currency: USD Updated: 2026-02-06

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. No risk assessment score is currently available for Moleculin Biotech Inc. The Biotechnology & Medical Research industry's average is 3.38. The company's beta value is 1.67. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. with an industry-leading ESG disclosure.